Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT 1 receptor blockade

Kidney and Blood Pressure Research

Volumn 30, Issue 1, 2007, Pages 38-44

  Vaněčková, Ivana ^a,c   Kopkan, Libor ^a   Husková, Zuzana ^a   Vaňourková, Zdenka ^a   Schejbalová, Stanislava ^a   Červenka, Luděk ^a   Kramer, Herbert J ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF BONN   (Germany)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Antihypertensive therapy; End organ damage; Receptor blocker, AT1, AT2; Ren 2 rats

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFICACY; HEART LEFT VENTRICLE; HEART VENTRICLE; HETEROZYGOSITY; HYPERTENSION; KIDNEY MASS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SALT INTAKE; SPRAGUE DAWLEY RAT; TRANSGENIC RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BENZIMIDAZOLES; BLOOD PRESSURE; HYPERTENSION, RENAL; KIDNEY; MALE; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN; TETRAZOLES;

EID: 33847021777     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098869     Document Type: Article

References (32)

1. Liu JG, Xu LP, Chu ZX, Miao CY, Su DF: Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens 2003;21:1961-1967.
2. Wu JN, Berecek KH: Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 1993;22:139-146.
3. Duke LM, Paull JR, Widdop RE: Cardiovascular status following combined angiotensin-converting enzyme and AT1 receptor inhibition in conscious spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2003;30:317-323.
4. Schnermann J, Briggs JP: Function of the juxtaglomerular apparatus: control of glomerular hemodynamics and renin secretion; in Seldin DW, Giebisch G (eds): The Kidney: Physiology and Pathophysiology, ed 3. Philadelphia, Lippincott, Williams & Wilkins, 2000, pp 945-980.
5. Yamori Y, Tarazi RC, Ooshima A: Effect of beta-receptor-blocking agents on cardiovascular structural changes in spontaneous and noradrenaline-induced hypertension in rats. Clin Sci (Lond) 1980;59(suppl 6):457s-460s.
6. Smeda JS, Lee RM, Forrest JB: Prenatal and postnatal hydralazine treatment does not prevent renal vessel wall thickening in SHR despite the absence of hypertension. Circ Res 1988;63:534-542.
7. Schiffrin EL: Vascular remodeling and endothelial function in hypertensive patients: effects of antihypertensive therapy. Scand Cardiovasc J Suppl 1998;47:15-21.
8. Mullins JJ, Peters J, Ganten D: Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344:541-544.
9. Siragy HM, Carey RM: The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997;100:264-269.
10. Carey RM: Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 2005;45:840-844.
11. Zhuo J, Ohishi M, Mendelsohn FA: Roles of AT1 and AT2 receptors in the hypertensive Ren-2 gene transgenic rat kidney. Hypertension 1999;33:347-353.
12. Nishioka T, Morris M, Li P, Ganten D, Ferrario CM, Callahan MF: Depressor role of angiotensin AT2 receptors in the (mRen-2) 27 transgenic rat. Am J Hypertens 1998;11:357-362.
13. Gigante B, Piras O, De Paolis P, Porcellini A, Natale A, Volpe M: Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens 1998;16:2039-2043.
14. Siragy HM, de Gasparo M, Carey RM: Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000;35:1074-1077.
15. Zicha J, Kunes J: Ontogenetic aspects of hypertension development: analysis in the rat. Physiol Rev 1999;79:1227-1282.
16. Bergstrom G, Johansson I, Wickman A, Gan L, Thorup C: Brief losartan treatment in young spontaneously hypertensive rats abates long-term blood pressure elevation by effects on renal vascular structure. J Hypertens 2002;20:1413-1421.
17. Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F, Lever AF: Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990;16:603-614.
18. Morton JJ, Beattie EC, MacPherson F: Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. J Vasc Res 1992;29:264-269.
19. Regan CP, Bishop SP, Berecek KH: Early, short-term treatment with captopril permanently attenuates cardiovascular changes in spontaneously hypertensive rats. Clin Exp Hypertens 1997;19:1161-1177.
20. Paull JR, Widdop RE: Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. J Hypertens 2001;19:1393-1402.
21. Lundie MJ, Friberg P, Kline RL, Adams MA: Long-term inhibition of the renin-angiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. J Hypertens 1997;15:339-348. 22 Kopkan L, Kramer HJ, Huskova Z, Vanourkova Z, Skaroupkova P, Thurmova M, Cervenka L: The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats. J Hypertens 2005;23:1531-1539.
22. Vaneckova I, Kramer HJ, Backer A, Vernerova Z, Opocensky M, Cervenka L: Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension 2005;46:969-974.
23. Opocensky M, Kramer HJ, Backer A, Vernerova Z, Eis V, Cervenka L, Certikova Chabova V, Tesar V, Vaneckova I: Late onset endothelin-A receptor blockade substantially improves survival rate in homozygous hypertensive Ren-2 rats. Hypertension 2006;48:965-971.
24. Heller J, Hellerova S: Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: a study in the Prague hypertensive rat. Kidney Blood Press Res 1998;21:445-451.
25. Červenka L, Heller J, Jelínek F: Lack of a beneficial effect of PD123319, an AT2-angiotensin receptor antagonist, on the course of ablation nephropathy in the rat. Kidney Blood Pressure Res 1996;19:241-243.
26. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, Poitevin P, Samuel JL: Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996;98:418-425.
27. Li JS, Touyz RM, Schiffrin EL: Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension 1998;31:487-492.
28. Bader M, Zhao Y, Sander M, Lee MA, Bachmann J, Bohm M, Djavidani B, Peters J, Mullins JJ, Ganten D: Role of tissue renin in the pathophysiology of hypertension in TGR (mREN2)27 rats. Hypertension 1992;19:681-686.
29. Macconi D, Ghilardi M, Bonassi ME, Mohamed EI, Abbate M, Colombi F, Remuzzi G, Remuzzi A: Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol 2000;11:477-489.
30. Tokita Y, Franco-Saenz R, Mulrow PJ, Ganten D: Effects of nephrectomy and adrenalectomy on the renin-angiotensin system of transgenic rats TGR(mRen2)27. Endocrinology 1994;134:253-257.
31. Campbell DJ, Kladis A, Valentijn AJ: Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995;26:233-240.
32. Huskova Z, Kramer HJ, Vanourkova Z, Cervenka L: Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J Hypertens 2006;24:517-527.